La vendita allo scoperto per Avalo Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Avalo Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Avalo Therapeutics (NASDAQ:AVTX) Azioni, Report sulle vendite allo scoperto

Avalo Therapeutics

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Inc

Avantium NV

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) is looking for Q4 Adj EPS of $0.48-0.51 vs $0.53 analyst estimate. seessales of $211.000 million-213.000 million vs $211.77 million estimate.

News

Guidance

Rapid7 Sees Q4 Adj EPS $0.48-0.51 vs $0.53 Est; Sees Sales $211.000M-213.000M vs $211.77M Est

Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. The company reported quarterly sales of $26.082 million which missed the analyst consensus estimate of $29.843 million by 12.60 percent. This is a 147.62 percent increase over sales of $10.533 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

RXRX

Recursion Pharmaceuticals Q3 2024 GAAP EPS $(0.34) Beats $(0.37) Estimate, Sales $26.082M Miss $29.843M Estimate

TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) lowers FY2024 Adj EPS guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 analyst estimate. Affirms FY2024 sales outlook from $2.21 billion-2.26 billion to $2.21 billion-2.26 billion vs $2.22 billion estimate.

TTEC

TTEC Holdings Lowers FY2024 Adj EPS Guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 Est; Affirms FY2024 Sales Guidance from $2.21B-2.26B to $2.21B-2.26B vs $2.22B Est

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) raises FY2024 Adj EPS guidance from $2.15-2.20 to $2.28-2.31 vs $2.17 analyst estimate. Raises FY2024 sales outlook from $833.00 million-837.00 million to $839.00 million-841.00 million vs $834.13 million estimate.

Rapid7 Raises FY2024 Adj EPS Guidance from $2.15-2.20 to $2.28-2.31 vs $2.17 Est; Raises FY2024 Sales Guidance from $833.00M-837.00M to $839.00M-841.00M vs $834.13M Est

Permian Resources Q3 Oil Sales $1.099B

Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) reported quarterly sales of $101.51 million which beat the analyst consensus estimate of $82.90 million by 22.44 percent. This is a 4.48 percent decrease over sales of $106.27 million the same period last year.

BRDG

Bridge Investment Group Q3 Sales $101.51M Beat $82.90M Estimate

CLOV

Clover Health Sees FY24 Adj. EBITDA Profitability $55M-$65M

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.71 by 15.2 percent. This is a 56.35 percent increase over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $593.74 million which missed the analyst consensus estimate of $613.63 million by 3.24 percent. This is a 5.96 percent increase over sales of $560.35 million the same period last year.

STRL

Sterling Infrastructure Q3 EPS $1.97 Beats $1.71 Estimate, Sales $593.74M Miss $613.63M Estimate

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent. The company reported quarterly sales of $122.751 million which missed the analyst consensus estimate of $125.853 million by 2.47 percent. This is a 3.99 percent decrease over sales of $127.854 million the same period last year.

NDLS

Noodles Q3 2024 Adj. EPS $(0.12) Misses $(0.06) Estimate, Sales $122.751M Miss $125.853M Estimate

Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $403.500 million which beat the analyst consensus estimate of $392.440 million by 2.82 percent. This is a 14.34 percent increase over sales of $352.900 million the same period last year.

Crane NXT Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $403.500M Beat $392.440M Estimate

Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17) by 29.41 percent.

Brookdale Senior Living Q3 2024 Adj. EPS $(0.22) Misses $(0.17) Estimate

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) raises FY2024 sales outlook from $432.00 million-438.00 million to $442.00 million-445.00 million.

VCYT

Veracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M  VS Est. 436.14M

CLNE

Clean Energy Fuels Sees FY24 Adj. EBITDA $62M-$72M

VIZIO Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZIO#NYSE">VZIO</a>) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.02) by 105 percent. The company reported quarterly sales of $444.70 million which beat the analyst consensus estimate of $443.80 million by 0.20 percent. This is a 4.34 percent increase over sales of $426.20 million the same period last year.

VZIO

VIZIO Holding Q3 2024 GAAP EPS $0.00 Beats $(0.02) Estimate, Sales $444.70M Beat $443.80M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) raises FY2025 sales outlook from $715.00 million-735.00 million to $737.00 million-739.00 million.

RAMP

LiveRamp Holdings Raises FY2025 Sales Guidance from $715.00M-735.00M to $737.00M-739.00M

Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $330.99 million which missed the analyst consensus estimate of $346.28 million by 4.42 percent. This is a 8.16 percent increase over sales of $306.03 million the same period last year.

Clover Health Investments Q3 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $330.99M Miss $346.28M Estimate

LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) sees Q3 sales of $191.000 million vs $188.55 million estimate.

LiveRamp Holdings Sees Q3 Sales $191.000M vs $188.55M Est

Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 89.66 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $1.39 million which missed the analyst consensus estimate of $1.48 million by 6.01 percent. This is a 30.98 percent increase over sales of $1.06 million the same period last year.

NYXH

Nyxoah Q3 EPS $(0.55) Misses $(0.46) Estimate, Sales $1.39M Miss $1.48M Estimate

Retail Sales

FTEK

Fuel Tech Inc Announced Orders From New And Existing Customers Totaling ~$2M

e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) shares are climbing after the company reported its second-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786513/e-l-f-beauty-announces-second-quarter-fiscal-2025-results">details from the report.  </a>
The Details: e.l.f. Beauty reported quarterly earnings of 77 cents per share, which beat the analyst consensus estimate of 42 cents. Quarterly revenue came in at $301.1 million, which beat the analyst consensus estimate of $285.76 million and is an increase over sales of $215.5 million from the same period last year.
e.l.f. said its gross margin increased approximately 40 basis points to 71%, primarily driven by cost savings, favorable foreign exchange impacts and price increases in the company&#8217;s international markets, partially offset by mix and higher transportation costs.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;Q2 marked another quarter of consistent, category-leading growth. In Q2, we delivered 40% net sales growth, fueled by 195 basis points of market share gains in the U.S. and 91% net sales growth internationally,&#8221; said Tarang Amin, e.l.f. Beauty&#8217;s CEO.
&#8220;This was our 23rd consecutive quarter of both net sales growth and market share gains. We continue to make progress across color cosmetics, skincare and international and believe our unique areas of advantage will fuel our ability to win in fiscal 2025 and beyond,&#8221; Amin added.
Outlook: e.l.f. Beauty raised its fiscal year 2025 net sales outlook to a range of $1.315 billion to $1.335 billion and now sees earnings of between $3.47 and $3.53 per share for the year.
ELF Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, e.l.f. Beauty shares are up 13.24% after-hours at $117.95 at the time of publication Wednesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Courtesy of E.l.f. Beauty, Inc.

Movers

e.l.f. Beauty Stock Soars After Strong Q2 Earnings Beat: Details

Avalo Therapeutics (AVTX) has issued an announcement. Avalo Therapeutics, Inc. has appointed the seasoned legal professional Paul Varki as their ne...

Avalo Therapeutics Welcomes New Chief Legal Officer Paul Varki

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Avalo Therapeutics (AVTX – Research Report), with a price t...

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

An update from Avalo Therapeutics (AVTX) is now available. Avalo Therapeutics has appointed Dr. Mittie Doyle as its new Chief Medical Officer, brin...

Avalo Therapeutics Welcomes New CMO with Competitive Package

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It could be quite beneficial to invest in personalized nutrition stocks for this month in July.



Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more <a href="https://www.futuremarketinsights.com/reports/personalized-nutrition-market">targeted</a> and therefore better advice on their diet.



New algorithms and AI are being designed and individual genetic, microbiome and biometric data are being used to design diets. Advancements include DNA and blood profiling of the consumer, where specific dietary suggestions can be provided based on the individual&rsquo;s biochemistry.&nbsp;



The global consumer is becoming more health <a href="https://www.snsinsider.com/reports/personalized-nutrition-market-3878">conscious</a> and seeking preventative measures to maintain their health and wellbeing. This shift is creating a need for products and services that are related to dietary counseling as per the consumer&rsquo;s need.



In order to meet these needs, companies are now spending their money on research and development to come up with new products; this includes personal care supplements, diet and even beverages made to fit certain styles.



These are durable trends in the market that will persist, so here are three personalized nutrition stocks for investors to consider that are riding high on them.



<h2>23andMe (ME)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/23andme-300x169.jpg" alt="A close-up shot of the saliva collection kit from 23andMe."><div>Source: nevodka / Shutterstock.com</div></div>23andMe (NASDAQ:<a href="https://investorplace.com/stock-quotes/me-stock-quote/">ME</a>) has a huge database of customers&rsquo; genetic information. It is primarily a therapeutics company, which makes it an attractive player in personalized nutrition stocks. Despite the fact that the company&rsquo;s consumer genetics kit business has experienced some <a href="https://investors.23andme.com/news-releases/news-release-details/23andme-reports-fourth-quarter-and-full-year-fiscal-2024">declines</a>, the main value of 23andMe can be found in its 14 million customers who can help to develop transformational drugs.



23andMe has an internal pipeline of several promising therapeutics: an antibody cancer drug and a NK cell activator that is already in the clinical trials.&nbsp;



It has also expanded the rest of its consumer genetics business, which includes a recently launched set of new premium features that offer users personal health information. The company&rsquo;s use of genetic information and pharmaceutical research gives it an edge in the fast-emerging field of personalized medicine and the potential for significant future revenues.



ME stock then is one of those personalized nutrition stocks to consider, as it combines a deep understanding of genetics and personalized medicine to offer nutritional insights.



<h2>Avalo Therapeutics (AVTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medicines-therapeutics-300x169.png" alt="Animated image of different medications"><div>Source: Olga Kononok/Shutterstock</div></div>Avalo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) is one of the best personalized nutrition stocks to consider now. Avalo is a clinical-stage biotech company, whose primary focus is to develop new therapies to manage immune dysregulation, with the goal of using the body&rsquo;s inflammatory pathways to treat various diseases.&nbsp;



The core of Avalo&rsquo;s pipeline consists of <a href="https://ir.avalotx.com/press-releases/detail/186/avalo-reports-first-quarter-2024-financial-results-and">AVTX-009</a>, a monoclonal antibody that the company claims to have a great prospect in treating hidradenitis suppurativa, or HS, a recurrent and usually painful inflammatory skin disease.&nbsp;



Avalo has high hopes for AVTX-009 based on its plans to progress it to a Phase II trial, which is expected to produce top line results in 2026.



Given that there is a large population of patients with unmet needs and a multi-billion dollar market opportunity in HS, approval of AVTX-009 may be a breakthrough in the treatment of this condition.&nbsp;



&nbsp;Of importance, Avalo has recently acquired AlmataBio and received $185 million financing. This has strengthened the company&rsquo;s capability and the company&rsquo;s cash runway into 2027. This, then, positions the company as one of those personalized nutrition stocks to buy.



<h2>Veracyte (VCYT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/healthy-food-300x169.jpg" alt="BSFC Stock. Healthy food including salmon, almonds, garlic, broccoli, avocado, and lettuce"><div>Source: Shutterstock.com</div></div>As one of the best personalized nutrition stocks to buy now, Veracyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/">VCYT</a>) is a company to watch. Being a global diagnostics company that is committed to revolutionizing cancer treatment, Veracyte&rsquo;s vision on the use of personalized medicine and nutrition is appropriate, given the increasing adoption of evidence-based, patient-specific approaches to healthcare.&nbsp;



The core of Veracyte&rsquo;s strategy is the <a href="https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-first-quarter-2024-financial-results">Veracyte Diagnostics Platform</a> &mdash; a combination of genomic and clinical data, bioinformatics and AI &mdash; that allows the company to create effective cancer tests. This enables Veracyte to develop therapies new and increase its range of personalized diagnostic tests leveraging the liquid biopsy.



VCYT&rsquo;s intersection with personalized nutrition is not as direct as some of the other companies on this list, but there is a strong enough synergy here with oncology to suggest it&rsquo;s one of those stocks to watch.



VCYT has also caught the attention of analysts, with positive earnings per share <a href="https://stockanalysis.com/stocks/vcyt/forecast/">forecasts</a> on the horizon and a growing top line.



On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> InvestorPlace.com Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/the-3-best-personalized-nutrition-stocks-to-buy-now/">The 3 Best Personalized Nutrition Stocks to Buy Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best Personalized Nutrition Stocks to Buy Now

Avalo Therapeutics GAAP EPS of -$14.07

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Avalo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) just reported results for the second quarter of 2024.<ul><li>Avalo Therapeutics reported earnings per share of -$14.07. This was below the analyst estimate for EPS of -$6.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/avtx-stock-earnings-avalo-therapeutics-for-q2-of-2024/">AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024

An update from Avalo Therapeutics (AVTX) is now available. At the 2024 Annual Meeting of the Company, a significant 58% of shareholders participate...

Avalo Therapeutics Shareholders Back Board and Strategies

Oppenheimer Sticks to Their Buy Rating for Avalo Therapeutics (AVTX)

Avalo Therapeutics (AVTX) has received a new Hold rating, initiated by H.C. Wainwright analyst, Edward White. Edward White's rating is based on a c...

Cautious Outlook on Avalo Therapeutics Amid Early-Stage Development and Financial Risks

H.C. Wainwright analyst Edward White initiated coverage of Avalo Therapeutics (AVTX) with a Neutral rating and no price target The firm says the co...

Comments

Avalo Therapeutics

Vendite allo scoperto

Avalo Therapeutics (NASDAQ:AVTX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO